Clinical trials
Phase 1/2 Schizophrenia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Recruiting | 4 |
| Suspended | 3 |
| Terminated | 3 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| New York State Psychiatric Institute | 4 |
| Novartis Pharmaceuticals | 2 |
| University of California, San Francisco | 2 |
| University of Colorado, Denver | 2 |
| VA Office of Research and Development | 2 |
| Vishwajit Nimgaonkar, MD PhD | 2 |
| Anya Bershad, MD, PhD | 1 |
| Beth Israel Deaconess Medical Center | 1 |
| Brian Miller | 1 |
| CoMentis | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Schizophrenia | 31 |
| Psychotic Disorders | 15 |
| Marijuana Abuse | 2 |
| Anxiety Disorders | 1 |
| Bipolar Disorder | 1 |
| Inflammation | 1 |
| Schizophrenia, Childhood | 1 |
| Schizotypal Personality Disorder | 1 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.